Evolve104
Vulvar Squamous Cell Carcinoma
EvolveImmune United, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Vulvar Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Christian Hinrichs | Phase 2 | B |
Fludarabine Christian Hinrichs | Phase 2 | B |
e7 tcr-t cells Christian Hinrichs | Phase 2 | B |
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE National Cancer Institute (NCI) | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Evolve104 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →